ProfileGDS5678 / 1458310_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 58% 56% 63% 54% 55% 59% 66% 56% 55% 55% 57% 55% 58% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5445858
GSM967853U87-EV human glioblastoma xenograft - Control 23.4040856
GSM967854U87-EV human glioblastoma xenograft - Control 33.7708163
GSM967855U87-EV human glioblastoma xenograft - Control 43.2925654
GSM967856U87-EV human glioblastoma xenograft - Control 53.3278355
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6229859
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0714666
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.399256
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3506455
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3645755
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.436157
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3362255
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5062658
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4183556